The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Open accessAbstract
BACKGROUND: The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial. METHODS: We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years. RESULTS: Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality were not reduced significantly. The incidence of major bleeding episodes was not significantly increased in the aspirin group (relative risk, 1.62; 95 percent confidence interval, 0.27 to 9.71). CONCLUSIONS: Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
Randomised trial of prophylactic daily aspirin in British male doctors
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. (1988) · BMJ · doi:10.1136/bmj.296.6618.313 · Cited by 1,166
Platelet Activation in Unstable Coronary Disease
Fitzgerald, D. J., Roy, L., Catella, F., & FitzGerald, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610163151602 · Cited by 1,141
Roncaglioni, M. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03539-x · Cited by 999
Aspirin as an Antiplatelet Drug
Wood, A. J. J., & Patrono, C. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301808 · Cited by 955
Self-citationThe RISC Group (1990) · The Lancet · doi:10.1016/0140-6736(90)92336-g · Cited by 781
Madden, C. (1991) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(05)81237-5 · Cited by 691
Hayden, M., Pignone, M., Phillips, C., & Mulrow, C. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-2-200201150-00016 · Cited by 627
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk, P. D., Goldberg, J. D., Donovan, P. B., Fruchtman, S. M., Berlin, N. I., & Wasserman, L. R. (1986) · PubMed · Cited by 493
Landolfi, R., Ciabattoni, G., Patrignani, P., Castellana, M., Pogliani, E., Bizzi, B., & Patrono, C. (1992) · Blood · doi:10.1182/blood.v80.8.1965.1965 · Cited by 142
Self-citationDissociation of Platelet Activation and Spontaneous Myocardial Ischemia in Unstable Angina
Véjar, M., Fragasso, G., Hackett, D. R., Lipkin, D. P., Maseri, A., Born, G. V. R., Ciabattoni, G., & Patrono, C. (1990) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1645038 · Cited by 118
Self-citationComplications of Injecting Dissolved Methylphenidate Tablets
Hahn, H. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300160046008 · Cited by 83
Low‐dose aspirin in polycythaemia vera: a pilot study
Policitemia, G. I. S. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.362682.x · Cited by 66
Cited by
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Self-citationVascular disorders of the liver # †
DeLeve, L. D., Valla, D.-C., & Garcia-Tsao, G. (2009) · Hepatology · doi:10.1002/hep.22772 · Cited by 978
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891
Metadata
- Authors
- Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 114-124
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2123587611
- Cited by
- 1,012
- References
- 16
- FWCI
- 24.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.